{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Src_Kinase_Inhibitor_M475271",
  "nciThesaurus": {
    "casRegistry": "476159-98-5",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An inhibitor of Src tyrosine kinase, with potential antineoplastic activity. Upon administration, Src kinase inhibitor M-475271 targets and binds to Src kinase. This inhibits Src-mediated signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival.",
    "fdaUniiCode": "0361Z8214O",
    "identifier": "C162339",
    "preferredName": "Src Kinase Inhibitor M475271",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1967"
    ],
    "synonyms": [
      "4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-",
      "AZM 475271",
      "AZM-475271",
      "AZM475271",
      "M 475271",
      "M-475271",
      "M475271",
      "N-(2-Chloro-5-methoxyphenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
      "Src Kinase Inhibitor M475271"
    ]
  }
}